At Nextgen Healthcare, Craig Barbarosh is Chair of the Compensation Committee and has seen firsthand the impact ESG has had on executive compensation. He talked about it with Corporate Board Member.
This article has been updated with corrections since it first appeared. Mylan, the generic and specialty pharmaceutical maker, last week agreed to consider a shareholder proposal that
For more and more companies, the question is no longer whether to grant long-term performance awards, but rather how to go about it.
An uptick in C-level departures, which includes several “involuntary retirements,” has compensation committees rethinking their approaches to officer-level severance pay.
Jonathan Szabo of Meridian Compensation Partners spoke with Corporate Board Member about how boards can navigate the uncharted territory of involuntary retirements from CEOs and how to craft their exit packages.
Remember when the fight over CEO pay revolved around performance? Now, Abigail Disney and her supporters seem to be saying performance doesn’t matter, either— it’s only about the pay.
